Lupin And Lilly Expand Partnership In India


Pharma major Lupin Limited (Lupin) has launched Cialis (tadalafil), an oral PDE5 inhibitor, for the treatment of erectile dysfunction (ED) in adult males. Cialis was shown to improve erectile function compared to placebo up to 36 hours following dosing. Cialis tablet is available in 10 mg and 20 mg strengths. The product is currently marketed in over 100 countries.

Lupin has acquired the rights to market, promote and distribute Lilly’s Erectile Dysfunction (ED) product, Cialis through its specialty field force while Lilly will be responsible for manufacturing and importing the product. Lupin is already promoting and distributing Lilly’s Huminsulin range of products and rapid acting insulin analog under the brand names Lispro and Eglucent.

The PDE-5 market in India is valued at around INR 390 crore, out of which Tadalafil contributes around 23%. The market size has doubled since 2012 and is growing annually at 15%. As per a study#, 52% men between the age 40 to 70 years suffer from erectile dysfunction (ED) of various type ranging from mild to severe. ED causes depression, low self-esteem and affects the quality of life.  

Commenting on the launch, Mr Rajeev Sibal, President - India Region Formulations, Lupin said, “We are very happy with the addition of Cialis to our business portfolio. It heralds Lupin’s entry into the fast growth PDE-5 inhibitors market which will address the unmet medical need in ED space in India. The launch demonstrates Lupin’s commitment to grow its brand franchise in India and bring meaningful products to patients in the country.”

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717  


Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.

0 comments: